NCT00968253: RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia |
|
|
| Completed | 1/2 | 24 | US | Everolimus (RAD001), Afinitor, Cyclophosphamide, Cytoxan, Neosar, Vincristine, Doxorubicin, Adriamycin, Rubex, Dexamethasone, Decadron, Mesna, Mesnex, Methotrexate, Ara-C (Cytarabine), Cytosar, DepoCyt, Cytosine Arabinosine Hydrochloride, Methylprednisone, Medrol, Depo-Medrol, Solu-Medrol, G-CSF, Filgrastim, Neupogen, Granulocyte Colony Stimulating Factor | M.D. Anderson Cancer Center, Novartis | Leukemia, Acute Lymphocytic Leukemia | 12/15 | 12/15 | | |
